Varex Imaging Corporation
VREXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeVarex Imaging Corporation designs, manufactures, and sells X-ray imaging components. Valued at $782.2M, VREX is a small-cap name in its sector. It operates through two segments, Medical and Industrial.
Market Cap
$782.2M
Beta
0.97
P/E (TTM)
34.75
P/E (Fwd)
17.21
EPS (TTM)
$0.53
EPS (Fwd)
$1.07
ROE
4.6%
ROA
4.2%
Cash
$100.1M
Total Debt
$379.3M
Free CF
-$39.5M
52W Change
54.5%
Annual Financials
Cash vs Debt
Where VREX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, VREX finished 51.68% above its 150-day moving average ($12.19) and 51.68% above its 200-day moving average ($12.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VREX overbought or oversold?
At the September 1, 2026 close, VREX's RSI(14) was 37.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Varex Imaging Corporation carries $379.3M in total debt against $100.1M in cash reserves — debt is roughly 3.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$39.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 4.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $859.4M (2022) to $844.6M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VREX.